Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 12,401–12,500 of 15,747
Türkoğlu, E., DEMİRAY, E. K. D., Yılmaz, D. Ç., Alkan, S., AKYÜZ, H. Ö., & Demir, O. (2022) · Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi · doi:10.17517/ksutfd.1053968 · Cited by 1
Campbell, P., Ess, G., Lale, A., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127781 · Cited by 1
Yuen, B. P., Wong, K., Cheung, H. W., Ho, E. N. M., & Wong, W. (2026) · Journal of Chromatography A · doi:10.1016/j.chroma.2026.467244 · Cited by 1
Cell Entry and Unusual Replication of SARS-CoV-2
McCann, N. R., & Castellino, F. (2022) · Current Drug Targets · doi:10.2174/1389450124666221014102927 · Cited by 3
Kong, X., & Wang, W. J. (2024) · Rheumatology & autoimmunity · doi:10.1002/rai2.12132 · Cited by 1
Cruz, J. P., de Carvalho, C. D. C. R., Silva, P. A. D. C., et al. (2022) · Hospital Pharmacy · doi:10.1177/00185787221111725 · Cited by 1
Zhu, Y., Gu, J., Qiu, Y., et al. (2022) · medRxiv · doi:10.1101/2022.08.08.22278571 · Cited by 1
Sahoo, D. P. (2025) · Cureus · doi:10.7759/cureus.82121 · Cited by 1
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiencyPreprint
Walz, J. S., Heitmann, J. S., Tandler, C., Marconato, M., Habibzade, T., Rittig, S. M., Tegeler, C. M., Nelde, A., Maringer, Y., Jäger, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1693355/v1 · Cited by 1
IgG level of the third booster dose for mRNA of SARS-CoV-2 vaccines among Iraqi healthcare workers
Rasheed, W. S., & Sarkees, A. N. (2023) · Medicine · doi:10.1097/md.0000000000035444 · Cited by 1
“Thus, the relationship between reactogenicity, immunogenicity, and the inflammatory response of the recently developed BNT162b2 vaccine must be determined.[8] Research has indicated that the level of anti-spike protein immunoglobulin G (IgG) and anti-spike receptor-binding domain (RBD) rises significantly, and antibod…”
BackgroundZinc‐Coordinated Lipids: Facilitators for Enhanced mRNA Delivery Efficacy
Zhang, Y., Su, K., Shi, L., Wu, S., Yan, X., Zhang, Y., Wang, Z., Wang, W., Xu, T., & Liu, S. (2025) · Angewandte Chemie · doi:10.1002/ange.202515406 · Cited by 1
Liu, Y., Sánchez‐Ovando, S., Carolan, L. A., Dowson, L., Khvorov, A., Hadiprodjo, A. J., Tseng, Y. Y., Delahunty, C., Khatami, A., Macnish, M., et al. (2023) · medRxiv · doi:10.1101/2023.06.02.23290871 · Cited by 1
Rousculp, M. D., Hollis, K. A., ZIEMIECKI, R. M., et al. (2024) · medRxiv · doi:10.1101/2024.06.25.24309259 · Cited by 1
Yoshifuji, A., & 竜崎, 崇. (2022) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.55.129 · Cited by 1
Recent advances in nanomedicines for chronic pain relief and management
Golmakani, E., Feyzi, P., Beygi, M. H. M., Vatankhah, A., Haghiralsadat, F., & Oroojalian, F. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119582 · Cited by 3
Denz, R., Meiszl, K., Ihle, P., Oberle, D., Drechsel‐Bäuerle, U., Scholz, K., Meyer, I., & Timmesfeld, N. (2025) · Communications in Statistics - Simulation and Computation · doi:10.1080/03610918.2025.2488942 · Cited by 2
Kawai, N., Bando, T., Goto, T., et al. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102852 · Cited by 1
Optimized workplace risk mitigation measures for SARS-CoV-2 in 2022
Pettit, R. W., Peng, B., Yu, P. L., Matos, P. G., Greninger, A. L., McCashin, J., & Amos, C. I. (2023) · Scientific Reports · doi:10.1038/s41598-023-29087-w · Cited by 1
Neilsen, G., Mathew, A. M., Castro, J. M., McFadden, W. M., Wen, X. R., Ong, Y. T., Tedbury, P. R., Lan, S., & Sarafianos, S. G. (2024) · mBio · doi:10.1128/mbio.03368-23 · Cited by 2
Treatment Approach, Pharmacological Agents and Vaccines
Tafoya, Q. J., Watson, V., Pawloski, J., Mohamed, G., & Ramadan, A. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-82691-4.00015-7 · Cited by 1
Tur‐Sinai, A., Bentur, N., Fabbietti, P., & Lamura, G. (2024) · European Journal of Ageing · doi:10.1007/s10433-024-00800-6 · Cited by 1
“Secondly, widespread use of vaccination began at the end of the year 2020 (Polack et al. 2020; Baden et al. 2021), an intervention that not only led to lower rates of infections, hospitalizations, and deaths (Haas et al. 2021), but also enabled the lowering of the restrictions that dramatically had…”
BackgroundA Hybrid SEIHCRDV-UKF Model for COVID-19 Prediction. Application on real-time dataPreprint
Papageorgiou, V. Ε., & Tsaklidis, G. M. (2022) · Research Square · doi:10.21203/rs.3.rs-1816184/v1 · Cited by 1
Poolchanuan, P., Tiacharoen, V., Dulsuk, A., Phunpang, R., Runcharoen, C., Boonprakob, T., Hemtong, O., Chowplijit, S., Chuapaknam, V., Siripoon, T., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4871864 · Cited by 1
An Overview of Lung Injury in Covid-19: Evaluating the Impact of Re-Exposure and Emerging Variants
Yadav, E. (2023) · Open Access Journal of Pulmonary & Respiratory Sciences · doi:10.23880/oajprs-16000161
Central Nervous System Neuroimmunologic Complications of COVID-19
Holroyd, K. B., & Conway, S. E. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1767713 · Cited by 1
Sim, J. K., Lee, H. S., Yang, J., Gwack, J., Kim, B. I., Cha, J.-O., Min, K. H., Lee, Y. S., & on behalf of the Severe Acute Respiratory Infection (SARI) Investigators (2024) · Journal of Korean Medical Science · doi:10.3346/jkms.2024.39.e128 · Cited by 3
mRNA Based Vaccine Studies in Infectious Diseases and Current Developments
Savaşçı, Ü., & Gül, H. C. (2021) · Journal of Molecular Virology and Immunology · doi:10.46683/jmvi.2020.19 · Cited by 1
COVID-19 VE DAVRANIŞSAL İKTİSAT: KÜRESEL BİR PANDEMİ SIRASINDA İNSAN DAVRANIŞINI ANLAMAK
ÇİLHOROZ, İ. A. (2023) · Sağlık ve Sosyal Refah Araştırmaları Dergisi · doi:10.55050/sarad.1301510 · Cited by 1
2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients
Bradwell, S. B., Hone, L., Thorneycroft, K., Lambourne, J., Aries, J. A., DAVIES, J. K., Cutiño‐Moguel, T., & Riches, J. C. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106908 · Cited by 2
Taylor, A., Michael, J., Sciarra, J., et al. (2023) · Cureus · doi:10.7759/cureus.35834 · Cited by 1
“In a large cohort of patients receiving the influenza vaccine, four out of 83 patients had unexpected fluorodeoxyglucose axillary node accumulations on imaging [4,9,8].”
BackgroundExploring Data and Literature Currently Available on the COVID-19 Vaccines
Gogia, P., Ashraf, H., Bhasin, S., & Frenia, D. S. (2022) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.55729/2000-9666.1001 · Cited by 1
Discovery and optimization of phenazopyridine hydrochloride as novel SARS-CoV-2 RdRp inhibitors
Zhao, J., Zhang, G., Li, Y., Ma, L., Yi, D., Li, Q., Shi, Y., Guo, S., Liu, T., Wang, Y., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117422 · Cited by 1
COVID-19 mRNA vaccine-induced lung injury: A case report
Luczynski, P., & Aboulhosn, K. (2022) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2022.2048979 · Cited by 1
Bean, D. J., Monroe, J., Liang, Y. M., Borberg, E., Senussi, Y., Swank, Z., Chalise, S., Walt, D. R., Weinberg, J., & Sagar, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.23.563621 · Cited by 1
Cacciottolo, M., Nice, J. B., Li, Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.10.523356 · Cited by 1
(2023) · Archives of Health Science · doi:10.31829/2641-7456/ahs2023-7(1)-017 · Cited by 2
Centorbi, C. S., Garau, E., Borsi, L., Brambilla, V., Brambilla, L., & Lazzeroni, D. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.109292 · Cited by 1
Kobara, I. D. L. R., Jayewickreme, R., Lee, M. J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.22.619639 · Cited by 1
Abounouh, K., Raji, T., Majidi, H., Redwane, S., Laazaazia, O., Aqillouch, S., Ouma, A. E. O., Abdulaziz, M., Aragaw, M., Fallah, M. P., et al. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-10345-9 · Cited by 2
Covid-19 Vaccine Benefits and Concerns: Nigerian Perspectives
Ayeotan, O. (2021) · Journal of Clinical and Medical Research · doi:10.37191/mapsci-2582-4333-3(5)-083 · Cited by 2
“The clinical trials of both BNT162b2 and mRNA-1273 vaccines have progressed to the third phase with the analysis of the study data showing vaccine efficacy of 94% and 95% against COVID-19 of any severity respectively [15,14].”
BackgroundCOVID-19 Vaccination and Acute Anterior Uveitis—A Case Control Study
Shemer, A., Toledano, A., Altarescu, A., Dubinsky‐Pertzov, B., Rozenberg, A., Hecht, I., Lifshitz, A. E., & Pras, E. (2025) · Vaccines · doi:10.3390/vaccines13020176 · Cited by 2
Vikström, L., Fjällström, P., Gwon, Y., Sheward, D., Wigren-Bystrom, J., Evander, M., Bladh, O., Widerstroem, M., Molnár, C., Rasmussen, G., et al. (2023) · medRxiv · doi:10.1101/2023.02.16.23286009
Jacobs, M. M., Karp, A., Alessandro, C., Ganz, M., Glatt, A. E., Rosenberg, A. Z., Wang, R., Zimmerman, J., Silverberg, J. I., & Zyskind, I. (2022) · Cureus · doi:10.7759/cureus.33190 · Cited by 1
“Vaccines for SARS-CoV-2 have proven to be highly effective at preventing severe disease and fatalities in the original and Alpha strains of COVID-19 [12-17].”
BackgroundReal-life observation of wildfire smoke–impaired COVID-19 vaccine immunity
Sanghar, G. K., Teuber, M. J., Ravindran, R. K., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.01.035 · Cited by 1
Wang, X., Luo, Q., Cao, B., Bai, H., Jia, Y., Ge, J., Wang, S., Weng, Y., Li, L., Ge, K., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.174966 · Cited by 1
Humoral response to mRNA ‐based COVID ‐19 vaccine in patients with immune thrombocytopenia
Mori, A., Onozawa, M., Kobayashi, M., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18578 · Cited by 1
Huang, P.-C., Chen, C.-H., Chien, C.-H., Chen, C.-H., & Chen, C.-Y. (2025) · International Journal of Breast Cancer · doi:10.1155/ijbc/8126974 · Cited by 1
COVID-19 Pandemic: Outbreak, Potential Vaccines And Medications
Bhat, R., Soliman, S. S. M., Ahmed, M. M. E., & Husseiny, M. I. (2021) · Russian Open Medical Journal · doi:10.15275/rusomj.2021.0401 · Cited by 1
MITIGATING THE 4 th WAVE OF THE COVID-19 PANDEMIC IN ONTARIOPreprint
Cipriano, L. E., Haddara, W. M. R., & Sander, B. (2021) · medRxiv · doi:10.1101/2021.09.02.21263000 · Cited by 1
“substantial protection against infection, markedly slowing disease transmission [17-21, 46, 47, 51, 55].”
BackgroundResultRaikhel, A. V., Blau, K., Alberty, K., & Redinger, J. W. (2022) · Cureus · doi:10.7759/cureus.27079 · Cited by 1
“A remarkable development to counter these outcomes has been the creation of safe and effective vaccines for COVID-19 [2,3].”
BackgroundHunziker, P. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3780070 · Cited by 1
Sputnik V Protection from COVID-19 of HIV-Infected Individuals Under ArtPreprint
Mazus, A. I., Gushchin, V. А., Tsyganova, E. V., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3949413 · Cited by 1
Lichen Planus after COVID-19 Vaccination
Alotaibi, S. H., Alharithy, R. S., Alsharif, F., et al. (2022) · Journal of Dermatology & Dermatologic Surgery · doi:10.4103/jdds.jdds_15_22 · Cited by 1
Wang, Y., Sun, J.-F., Fu, H.-T., Shao, Z.-J., Wang, C.-Y., Zhu, G., Bai, L.-P., Jiang, Z., & Zhang, W. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c06592 · Cited by 2
Sarkardeh, M., Rezapanah, A., Ayati Afin, A., Shamshirian, A., Sadrzadeh, Z., Koushki, J., & Dalili, A. (2022) · Iranian Red Crescent Medical Journal · doi:10.32592/ircmj.2022.24.12.2246 · Cited by 1
Inactivated COVID-19 vaccine-related herpes zoster and postherpetic neuralgia; three case reports
Kanar, M. (2022) · Ağrı - The Journal of The Turkish Society of Algology · doi:10.14744/agri.2021.66642 · Cited by 2
Hirota, M., Tamai, M., Yukawa, S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.08.503075 · Cited by 1
mRNA vaccines for COVID-19 are safe and clinically effective in patients with cardiac amyloidosis
Barzen, G., Rieber, F., Stangl, K., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.12.041 · Cited by 1
Cernigliaro, M., Negroni, D., Sassone, M., Paladini, A., Carriero, A., Saba, L., & Guzzardi, G. (2021) · Journal of Public Health Research · doi:10.4081/jphr.2021.2265 · Cited by 1
Blain, H., Tuaillon, É., Pisoni, A., Soriteau, L., Million, E., Léglise, M.-S., Bussereau, I., Miot, S., Rolland, Y., Picot, M., et al. (2021) · medRxiv · doi:10.1101/2021.09.21.21263880 · Cited by 1
COVID-19 vaccine utilizing the technology of gene therapy
中神, 啓., & 森下, 竜. (2022) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.59.34 · Cited by 1
COVID vaccine use in inpatient psychiatry units—The need is here and now
Li, L., Kulp, W., Goldman, M. L., Sernyak, M. J., Petrakis, I. L., & Runnels, P. S. (2021) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2021.03.011 · Cited by 1
Lv, K., Qi, Y., Zhao, H., Zhang, Y., An, Z., Ma, S., & Song, W. (2025) · Chemical Science · doi:10.1039/d5sc04801j · Cited by 1
Brief Epidemiological Consideration on the COVID-19 Pandemic
Shinoda, S. (2023) · Journal of Disaster Research · doi:10.20965/jdr.2023.p0069 · Cited by 1
Ernst, F. R., McGrath, L. J., Reimbaeva, M., et al. (2025) · Infectious Diseases and Therapy · doi:10.1007/s40121-025-01259-3 · Cited by 1
“COVID-19 vaccines and antiviral therapy have been key strategies in decreasing the public health impact of SARS-CoV-2 infection [5–12].”
Marchese, A. M., Zhou, X., Kinol, J., et al. (2023) · medRxiv · doi:10.1101/2023.03.17.23287306 · Cited by 1
Li, X.-T., Martínez-Hernández, E., Herranz, E. R., Delmestri, A., Duarte-Salles, T., Strauss, V. Y., Burn, E., & Prieto-Alhambra, D. (2021) · medRxiv · doi:10.1101/2021.09.08.21263276
Freeman, D. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-80932-0.00146-4 · Cited by 1
Ketaren, N. E., Mast, F. D., Fridy, P. C., Olivier, J. P., Sanyal, T., Sali, A., Chait, B. T., Rout, M. P., & Aitchison, J. D. (2023) · doi:10.1101/2023.07.14.549041 · Cited by 1
Soegiarto, G., Fajar, J. K., Wulandari, L., Anshory, M., Ilmawan, M., Asmiragani, A., Illiyana, H., Adam, A., Lamadi, S., Sa'adah, U., et al. (2022) · F1000Research · doi:10.12688/f1000research.110281.1 · Cited by 1
Harnessing the Power of Venomous Animal-Derived Toxins against COVID-19
de Oliveira, I. S., Ferreira, I. G., Jacob, B. D. C. D. S., Cardenas, K. C. T., Cerni, F. A., Baía-da-Silva, D. C., Arantes, E. C., Monteiro, W. M., & Pucca, M. B. (2023) · Toxins · doi:10.3390/toxins15020159 · Cited by 2
“Currently, some vaccines were granted authorization in the USA: BNT162b2 vaccine (mRNA-based, BioNTech/Pfizer, New York, NY, USA) [57], mRNA-1273 vaccine (mRNA based, Moderna, Cambridge, MA, USA) [58], and Ad26.”
Insights into COVID-19 vaccines development: Translation from benchside to bedside
Houssein, M., Hossainy, A. E. A. A., soussi, J. A., Batch, J. E., El‐Samadi, L., Imam, S. E., Fakih, R., Dakdouk, H., & Khalil, M. I. M. (2022) · Health Sciences Review · doi:10.1016/j.hsr.2022.100040 · Cited by 2
Lin, C., Lin, M., Yang, X., Chiang, H.-H., Wu, T.-H., Tsai, C.-H., & Lin, C. (2025) · Analytica Chimica Acta · doi:10.1016/j.aca.2025.344623 · Cited by 1
Liebers, N., Schönland, S. O., Speer, C., Edelmann, D., Schnitzler, P., Kräusslich, H., Müller‐Tidow, C., Hegenbart, U., & Dietrich, S. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000688 · Cited by 1
Chen, G., Nguyen, T., McKay, L. G. A., Nakka, S. S., Hu, P., McBride, J., Liang, A. C. T., Olson, R. M., Moon, J. J., Luster, A. D., et al. (2025) · Science Advances · doi:10.1126/sciadv.adx0037 · Cited by 5
Martín‐Sánchez, E., Tamariz‐Amador, L., Guerrero, C., Zherniakova, A., Zabaleta, A., Maia, C., Blanco, L., Alignani, D., Fortuño, M.-A., Grande, C., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01089-5 · Cited by 2
Antwi, K., Caobelli, F., Kudura, K., et al. (2023) · Nuklearmedizin - NuclearMedicine · doi:10.1055/s-0043-1766371 · Cited by 1
Considerations in the Management of Covid-19 in Patients with Chronic Kidney Disease
Joshua, C., Hasni, K., & Hafiz, S. (2022) · Annals of Nephrology · doi:10.36959/832/410
“Large scale randomized trials assessing the efficacy of Tozinameran have found 95% reduction in infection for individuals 16 years and older at 2 months, 90% at 2-4 months, and 84% at 4-6 months [8 , 9] .”
Ngonghala, C. N., & Asare-Baah, M. (2022) · medRxiv · doi:10.1101/2022.07.06.22277303 · Cited by 1
“With high efficacies of ≈ 95% for the mRNA vaccines and ≈ 70% for the adenovirus-based vaccine against the non-variant (wild-type) strain of SARSCoV-2, these vaccines have effectively prevented moderate to severe symptomatic disease, hospitalization, and death [10, 14, 17, 20, 21].”
BackgroundMiller, D. A., Duncan, L., Termini, L., Prebil, L. A., Witt, D. J., & McCurdy, S. A. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad048 · Cited by 1
“Another limitation of the study was that Facility 1 staff were vaccinated on Outbreak Day 7, with expectations for vaccine protection to commence 12 days later [17].”
BackgroundEfficacy and safety parameters of a novel COVID-19 vaccine
Privatpraxis, I. T. 1., Riedel-Baima, B., Zieliński, R., et al. (2021) · Frontiers in Molecular Immunology · doi:10.25082/fmi.2021.01.001 · Cited by 1
Lister, H., Farquharson, K., Seale, H., Smith, L. E., Poletti, T., Amin, F., & Rubin, G. J. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128195 · Cited by 2
Liu, D., Gilliland, J., Nakaya, T., Kan, Z., Nagata, S., & Huang, J. (2025) · Applied Spatial Analysis and Policy · doi:10.1007/s12061-025-09773-0 · Cited by 2
“(2020) demonstrated 95% protection against COVID-19 in individuals aged 16 years or older.”
InfluentialMamrovskaya, T. (2021) · Dalʹnevostočnyj medicinskij žurnal · doi:10.35177/1994-5191-2021-3-6-12 · Cited by 1
Gleinich, A. S., Pepi, L. E., Shajahan, A., et al. (2021) · PubMed · Cited by 1
Guia prático do tratamento com omalizumabe para urticária crônica espontânea
Melo, J. M. L., Borges, L., França, A. T., et al. (2020) · Arquivos de Asmas Alergia e Imunologia · doi:10.5935/2526-5393.20200045 · Cited by 1
Dose-dependent IFN programs in myeloid cells after mRNA and adenovirus COVID-19 vaccination
Eryilmaz, G. N., Yazıcı, Y. Y., Marcheş, R., Mimitou, E. P., Kenyon‐Pesce, L., Handrejk, K., Jangra, S., Schotsaert, M., García‐Sastre, A., Kuchel, G. A., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.199245 · Cited by 1
Huppke, L., Gebhardt, C., Grümme, L., Lichtnekert, J., Singh, D., Ullrich, F., Wolfrum, S., Skapenko, A., & Schulze‐Koops, H. (2025) · Rheumatology International · doi:10.1007/s00296-025-06013-z · Cited by 1
“However, data on potential interactions of the vaccines with IRDs or with their therapies were not available because patients with IRDs were excluded from the pivotal trials [3–5].”
史人, 加., Sekihara, K., 竜哉, 岡., 玲央, 井., Kojimahara, T., 樹, 植., & 昭夫, 木. (2022) · Nihon Kyukyu Igakukai Zasshi Journal of Japanese Association for Acute Medicine · doi:10.1002/jja2.12728 · Cited by 1
Shoham, S., Focosi, D., Franchini, M., & Atamna, A. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2436973 · Cited by 1
“With their excellent safety profile and efficacy rates exceeding 90% in the general population, the mRNA vaccines have become the most commonly used anti-SARS-CoV-2 vaccine products [18,19].”
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.